Key result
Vasopressin raises systolic BP ~18 mm Hg in Fontan patients while reducing pulmonary vascular resistance.
Why the study?
The acute hemodynamic effects of vasopressin on the Fontan circulation were not well described.
Does vasopressin alter acute hemodynamics in patients with a Fontan circulation?
Does vasopressin alter acute hemodynamics in patients with a Fontan circulation?
Vasopressin administration in Fontan patients acutely increases systemic blood pressure and systemic vascular resistance while decreasing pulmonary vascular resistance without compromising cardiac index, suggesting utility for treating systemic hypotension during anesthesia.
Answers are grounded in this paper and cite their sources.
Vasopressin effects on Fontan hemodynamics remain preliminary; hypothesis-generating data should not yet change practice.
Objective To describe the acute hemodynamic effect of vasopressin on the Fontan circulation, including systemic and pulmonary pressures and resistances, left atrial pressure, and cardiac index. Design Prospective, open-label, nonrandomized study (NCT04463394). Setting Cardiac catheterization laboratory at Lucile Packard Children's Hospital, Stanford. Patients Patients 3-50 years old with a Fontan circulation who were referred to the cardiac catheterization laboratory for hemodynamic assessment and/or intervention. Interventions A 0.03 U/kg IV (maximum dose 1 unit) bolus of vasopressin was administered over 5 minutes, followed by a maintenance infusion of 0.3 mU/kg/min (maximum dose 0.03 U/min). Measurements and main results Comprehensive cardiac catheterization measurements before and after vasopressin administration. Measurements included pulmonary artery, atrial, and systemic arterial pressures, oxygen saturations, and systemic and pulmonary flows and resistances. There were 28 patients studied. Median age was 13.5 (9.1, 17) years, and 16 (57%) patients had a single or dominant right ventricle. Following vasopressin administration, systolic blood pressure and systemic vascular resistance (SVR) increased by 17.5 (13.0, 22.8) mm Hg ( Z value -4.6, p < 0.001) and 3.8 (1.8, 7.5) Wood Units ( Z value -4.6, p < 0.001), respectively. The pulmonary vascular resistance (PVR) decreased by 0.4 ± 0.4 WU ( t statistic 6.2, p < 0.001), and the left atrial pressure increased by 1.0 (0.0, 2.0) mm Hg ( Z value -3.5, p < 0.001). The PVR:SVR decreased by 0.04 ± 0.03 ( t statistic 8.1, p < 0.001). Neither the pulmonary artery pressure (median difference 0.0 [-1.0, 1.0], Z value -0.4, p = 0.69) nor cardiac index (0.1 ± 0.3, t statistic -1.4, p = 0.18) changed significantly. There were no adverse events. Conclusions In Fontan patients undergoing cardiac catheterization, vasopressin administration resulted in a significant increase in systolic blood pressure, SVR, and left atrial pressure, decrease in PVR, and no change in cardiac index or pulmonary artery pressure. These findings suggest that in Fontan patients vasopressin may be an option for treating systemic hypotension during sedation or general anesthesia.
No takes yet. Share an insight, caveat, or question.
Adamson et al. (2023) studied Fontan circulation (n=28). Vasopressin vs. Pre-administration baseline was evaluated on Acute hemodynamic changes (systolic blood pressure, systemic vascular resistance, pulmonary vascular resistance, left atrial pressure, PVR:SVR ratio, pulmonary artery pressure, and cardiac index) (MD -0.4 WU for PVR; median increase 17.5 mm Hg for SBP and 3.8 WU for SVR, p=<0.001). Vasopressin in Fontan patients increased systolic BP and SVR and decreased PVR, without altering cardiac index.
Synapse has enriched 10 related papers. Consider them for comparative context: